Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
CXCR4 antagonist (HSC mobiliser)

Plerixafor

Brand names: Mozobil

Plerixafor is a haematopoietic stem cell mobiliser used, in combination with G-CSF, to mobilise stem cells into the peripheral blood for autologous transplantation in lymphoma and multiple myeloma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a reversible antagonist of the CXCR4 chemokine receptor, blocking its interaction with stromal SDF-1 (CXCL12) in the bone marrow and releasing CD34-positive stem cells into the circulation.

Prescribing in practice

  • It is intended only for autologous mobilisation and should not be used in leukaemia because of the theoretical risk of mobilising malignant cells; splenic enlargement and rupture have been reported.
  • Dose adjustment is required in significant renal impairment as clearance is predominantly renal.
  • It is given by subcutaneous injection in the evening before apheresis, in combination with G-CSF, per the SPC.

Monitoring

Monitor peripheral CD34-positive cell counts to time apheresis, alongside full blood count and for injection-site and gastrointestinal reactions.

Counselling the patient

  • Explain the timing of the injection relative to stem cell collection the following day.
  • Advise reporting left upper abdominal or shoulder-tip pain, which could indicate a splenic problem.

Evidence & guidelines

Randomised trials demonstrated that adding plerixafor to G-CSF improves CD34-positive stem cell yields for autologous transplantation.

Reference: NICE TA483; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways